The TCA mosaic is a technical illustration of the Correction phase, showing how active treatment can be graduated and localized to prevent demarcation lines. In daily practice, however, the dermo-functional continuum (Correction → Stabilization → Maintenance) is implemented using phase-specific clinical tools.
Clinical objective:
Target active pathological or functional skin disorders.
This phase focuses on direct intervention on visible and underlying skin alterations such as structural damage, dyschromias, inflammatory conditions, acne, scars, or loss of dermal signaling.
Role of products:
Active correction only.
Clinical objective:
Consolidate results and restore skin functional balance.
This phase aims to normalize skin physiology, reinforce the barrier function, regulate inflammation, control pigmentation pathways, and reduce the risk of relapse.
Role of products:
Functional normalization and result consolidation.
Clinical objective:
Maintain results over time and prevent recurrence.
This phase ensures long-term skin balance, preserves anti-aging benefits, supports controlled stimulation, and integrates home-care continuity.
Role of products:
Protection, support, and prevention.
Each step of the dermo-functional continuum relies on a dedicated product strategy — not interchangeable products.
Active clinical correction phase: targeted protocols designed to address priority skin concerns.
View ProductFunctional modulation phase: barrier support and controlled normalization to reduce relapse risk.
View ProductLong-term maintenance: preserves gains, supports skin stability, and integrates into home-care continuity.
View ProductNote: Products are selected according to their primary role within the protocol phase and are not meant to be swapped without clinical rationale.